The use of bisphosphonates in women prior to or during pregnancy and lactation

Hormones

Volumn 10, Issue 4, 2011, Pages 280-291

  Ioannis, Stathopoulos P ^a   Chrysoula, Liakou G ^a   Aikaterini, Katsalira ^a   George, Trovas ^a   George, Lyritis P ^a   Nikolaos, Papaioannou A ^a   Symeon, Tournis ^a  

^a KAT HOSPITAL   (Greece)

Author keywords

Bisphosphonates; Lactation; Pregnancy

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; CYCLOSPORIN; ETIDRONIC ACID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; MEDRONATE TECHNETIUM TC 99M; MORPHINE; NERIDRONIC ACID; PAMIDRONIC ACID; RADIOISOTOPE; RISEDRONIC ACID; SALAZOSULFAPYRIDINE; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADVERSE OUTCOME; ALBRIGHT SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; AVASCULAR NECROSIS; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; BREAST FEEDING; CONGENITAL DISORDER; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG USE; ENTERITIS; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; GAUCHER DISEASE; GESTATIONAL AGE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; IDIOPATHIC HYPERPHOSPHATASIA; INFANT; LACTATION; LIVE BIRTH; LOW BIRTH WEIGHT; MALIGNANCY ASSOCIATED HYPERCALCEMIA; MALIGNANT HYPERCALCEMIA; MULTIPLE CYCLE TREATMENT; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PELVIS FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; PREGNANCY; PREGNANCY ASSOCIATED OSTEOPOROSIS; PRENATAL DRUG EXPOSURE; SPONTANEOUS ABORTION; SYMPATHETIC DYSTROPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VERTEBRA FRACTURE;

EID: 84855517874     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1319     Document Type: Article

References (44)

1. Top 200 brand-name drugs by units in 2006 www.drugtopics.com/drugtopics/Pharmacy+Facts+And+Figures/Top-200-brand-name-drugs-by-units-in-2006.
2. Drake MT, Clarke BL, Khosla S, 2008 Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83: 1032-1045.
3. Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A, 1999 Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60: 68-73.
4. Minsker DH, Manson JM, Peter CP, 1993 Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 121: 217-223.
5. Graepel P, Bentley P, Fritz H, Miyamoto M, Slater SR, 1992 Reproduction toxicity studies with pamidronate. Arzneimittelforschung 42: 654-667.
6. Ornoy A, Wajnberg R, Diav-Citrin O, 2006 The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22: 578-579.
7. Levy S, Fayez I, Taguchi N, et al, 2009 Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44: 428-430.
8. Losada I, Sartori L, Di Gianantonio E, Zen M, Clementi M, Doria A, 2010 Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age? Autoimmun Rev 9: 547-552.
9. Chan B, Zacharin M, 2006 Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91: 2017-2020.
10. Munns CF, Rauch F, Ward L, Glorieux FH, 2004 Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19: 1742-1745.
11. Hassen-Zrour S, Korbaa W, Bejia I, Saidani Z, Bergaoui N, 2010 Maternal and fetal outcome after long-term bisphosphonate exposure before conception. Osteoporos Int 21: 709-710.
12. Harsch IA, Hubner RH, Hahn EG, Hensen J, 2001 [Osteoporosis and multiple pregnancy--a case report with positive outcome]. Med Klin (Munich) 96: 402-407.
13. Athimulam S, Chan P, Baker M, Nauta M, Yoong W, 2007 The effect of pregnancy on pre-existing osteopenia: a case report. Arch Gynecol Obstet 276: 175-177.
14. Vujasinovic-Stupar N, Pejnovic N, Markovic L, Zlatanovic M, 2011 Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome. Rheumatol Int, in press.
15. Cabar FR, Nomura RM, Zugaib M, 2007 Maternal and fetal outcome of pamidronate treatment before conception: a case report. Clin Exp Rheumatol 25: 344-345.
16. Rutgers-Verhage AR, deVries TW, Torringa MJ, 2003 No effects of bisphosphonates on the human fetus. Birth Defects Res A Clin Mol Teratol 67: 203-204.
17. Mastaglia SR, Watman NP, Oliveri B, 2010 Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health. Osteoporos Int 21: 1959-1962.
18. Biswas PN, Wilton LV, Shakir SA, 2003 Pharmacovigilance study of alendronate in England. Osteoporos Int 14: 507-514.
19. Dunlop DJ, Soukop M, McEwan HP, 1990 Antenatal administration of aminopropylidene diphosphonate. Ann Rheum Dis 49: 955.
20. Illidge TM, Hussey M, Godden CW, 1996 Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 8: 257-258.
21. Andreadis C, Charalampidou M, Diamantopoulos N, Chouchos N, Mouratidou D, 2004 Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer. Gynecol Oncol 95: 252-255.
22. Culbert EC, Schfirin BS, 2006 Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. Obstet Gynecol 108: 789-791.
23. Siminoski K, Fitzgerald AA, Flesch G, Gross MS, 2000 Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res 15: 2052-2055.
24. Hedrick WR, DiSimone RN, Wolf BH, Langer A, 1998 Absorbed dose to the fetus during bone scintigraphy. Radiology 168: 245-248.
25. Palestro CJ, Malat J, Collica CJ, Richman AH, 1986 Incidental diagnosis of pregnancy on bone and gallium scintigraphy. J Nucl Med 27: 370-372.
26. McKenzie AF, Budd RS, Yang C, Shapiro B, Hicks RJ, 1994 Technetium-99m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation. J Nucl Med 35: 1338-1341.
27. Black AJ, Topping J, Durham B, Farquharson RG, Fraser WD, 2000 A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res 15: 557-563.
28. Kovacs C, 2006 Skeletal physiology: fetus and neonate. Primer on the metabolic bone diseases and disorders of mineral metabolism, pp; 50-55.
29. Nancollas GH, Tang R, Phipps RJ, et al, 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38: 617-627.
30. Dunford JE, Thompson K, Coxon FP, et al, 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235-242.
31. Lin JH, 1996 Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75-85.
32. Cremers SC, Pillai G, Papapoulos SE, 2005 Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44: 551-570.
33. Kimmel DB, 2007 Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86: 1022-1033.
34. Khan SA, Kanis JA, Vasikaran S, et al, 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12: 1700-1707.
35. Papapoulos SE, Cremers SC, 2007 Prolonged bisphosphonate release after treatment in children. N Engl J Med 356: 1075-1076.
36. Peris P, Torra M, Olivares V, et al, 2011 Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone 49: 706-709.
37. Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C, 2003 Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33: 301-307.
38. Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE, 1995 Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 80: 3465-3468.
39. Bone HG, Hosking D, Devogelaer JP, et al, 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189-1199.
40. Black DM, Schwartz AV, Ensrud KE, et al, 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927-2938.
41. Watts NB, Chines A, Olszynski WP, et al, 2008 Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19: 365-672.
42. Guyton A 1992. Medical Physiology, Paschalidis eds, Athens; pp, 1205-1207.
43. Reid DM, Devogelaer JP, Saag K, et al, 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373: 1253-1263.
44. Ott SM, 2004 Effects of bisphosphonates during pregnancy. http://courses.washington.edu/bonephys/oppregnancy.html#Bis. 2010 November, 26.